Pharmathene, Inc.
Formerly Healthcare Acquisition Corp.
Pharmathene, Inc. is listed today as Altimmune, Inc.: market value, financials and filings are on its company page.
Funding rounds
2 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Nov 2010 | $10 M | No. 2 | $2 to $10 million | equity | SEC | |
| Jul 2009 | $19 M | No. 1 | $10 to $50 million | debt, options | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Pharmathene, Inc. chose not to state its revenue in its newest notice of a funding round (Nov 2010).
SEC Form D · Nov 2010
The industry group it chose in its notices: Pharmaceuticals.
SEC Form D · Nov 2010
That is all the official record says: Pharmathene, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services of Pharmathene, Inc. are on record.
Investors#
No investor of Pharmathene, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 22 investors.
Largest shareholders today
Institutions holding Altimmune, Inc. shares, as of Sep 30, 2026.
- BlackRock, Inc.$60 M10.77%
- Deep Track Capital, LP$55 M9.89%
- State Street Corp$24 M4.29%
- Vanguard Portfolio Management LLC$23 M4.17%
- Vanguard Capital Management LLC$22 M4.02%
- Viking Global Investors LP$19 M3.44%
- Ra Capital Management, L.P.$19 M3.34%
- Marshall Wace, LLP$16 M2.79%
- Geode Capital Management, LLC$14 M2.51%
- Two Sigma Investments, LP$12 M2.18%
- Trails Edge Capital Partners, LP$12 M2.17%
- Millennium Management LLC$11 M1.98%
- Woodline Partners LP$10 M1.75%
- Goldman Sachs Group Inc$7 M1.27%
- Nuveen, LLC$6 M1.10%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Charles A. Reinhart III | Executive officer | Nov 2010 |
| Eric I. Richman | Executive officer | Nov 2010 |
| Francesca H. Cook | Executive officer | Nov 2010 |
| Joan R. Fusco | Executive officer | Nov 2010 |
| Jordan P. Karp | Executive officer | Nov 2010 |
| Thomas R. Fuerst | Executive officer | Nov 2010 |
| Valerie A. Riddle | Executive officer | Nov 2010 |
| Wayne P. Morges | Executive officer | Nov 2010 |
| Christopher C. Camut | Executive officer | Aug 2009 |
| David P. Wright | Executive officer | Aug 2009 |
| Francesca Cook | Executive officer | Aug 2009 |
| Joan Fusco | Executive officer | Aug 2009 |
| Valerie C. Riddle | Executive officer | Aug 2009 |
| Wayne Morges | Executive officer | Aug 2009 |
| Derace L. Schaffer | Director | Nov 2010 |
| Eric I. Richman | Director | Nov 2010 |
| James H. Cavanaugh | Director | Nov 2010 |
| Jeffrey W. Runge | Director | Nov 2010 |
| Joel I. McCleary | Director | Nov 2010 |
| John I. Gill | Director | Nov 2010 |
| John Pappajohn | Director | Nov 2010 |
| Mitchel W. Sayare | Director | Nov 2010 |
| Steven H. St. Peter | Director | Nov 2010 |
| David P. Wright | Director | Aug 2009 |
| Joel McCleary | Director | Aug 2009 |
| John Gill | Director | Aug 2009 |
| Steven St. Peter | Director | Aug 2009 |
Went public since 2012. Its SEC number is that of a company listed on a stock exchange.